News|Articles|November 20, 2026

Emerging Therapeutic Targets Take Center Stage at DermNexus 2026

NP/PA Connect
Listen
0:00 / 0:00

Key Takeaways

  • CSU algorithms prioritize second-generation H1 antihistamines with up-dosing; H2 blockers and mast-cell stabilizers are de-emphasized, with cyclosporine reserved for selected refractory patients.
  • Biologic and targeted CSU options span anti-IgE (omalizumab), IL-4Rα blockade (dupilumab), and BTK inhibition (remibrutinib), requiring bleeding/bruising counseling due to platelet-signaling effects.
SHOW MORE

DermNexus 2026 experts explored advances in CSU management and targeted nonsteroidal therapies for psoriasis, atopic dermatitis, and vitiligo.

During the second session of DermNexus 2026, faculty explored advances in chronic spontaneous urticaria management and nonsteroidal topical therapies for inflammatory skin diseases.

As the therapeutic landscape for inflammatory skin diseases continues to expand, advances in targeted treatments are creating new opportunities to address persistent symptoms, improve disease control, and individualize patient care. From novel approaches to mast-cell activation in chronic spontaneous urticaria (CSU) to an expanding range of nonsteroidal topical therapies, clinicians have an increasingly diverse set of treatment options to consider.

During "Spotlight on Targets in Dermatologic Diseases," the second educational session of DermNexus 2026: The Inflammatory Disease and Innovations Congress for NP/PAs, held November 20–21 in Scottsdale, Arizona, Daniel Butler, MD; Robert J. Casquejo, PA-C; and David Seiter, FNP-C, DCNP, examined evolving therapeutic approaches and their implications for clinical practice.

The session explored histamine-mediated and neuroimmune pathways in CSU, alongside advances in topical Janus kinase (JAK) inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and aryl hydrocarbon receptor (AhR) agonists. Throughout the discussion, faculty emphasized how understanding mechanisms of action can inform treatment selection, patient counseling, and long-term disease management.

Rethinking the Treatment Algorithm for Chronic Urticaria

The session began with an examination of the mechanisms underlying CSU, including mast-cell activation, histamine release, and the contribution of neuroimmune signaling to persistent itching.

Faculty explained that although histamine plays a central role in urticaria, it may not fully account for the clinical presentation of every patient. Some individuals experience rapid-onset itching and wheals that respond well to antihistamines, whereas others have symptoms that may involve additional inflammatory or neural pathways.

Importantly, these patterns may vary within the same patient, even between episodes.

The discussion emphasized the potential value of evaluating symptom characteristics and treatment response when considering the mechanisms contributing to disease activity.

Current international treatment algorithms discussed during the session begin with second-generation H1 antihistamines, with dose escalation up to 4 times the standard dose when symptoms remain inadequately controlled.

However, faculty noted that antihistamine escalation does not provide adequate relief for every patient, reinforcing the need for additional therapeutic strategies.

The presenters also highlighted changes in the treatment algorithm, including the exclusion of H2 blockers and mast-cell stabilizers from the recommendations discussed.

For patients with persistent disease, the algorithm progresses toward biologic or targeted treatments, with cyclosporine remaining a consideration in selected refractory cases.

Expanding Targeted Treatment Options for CSU

The faculty reviewed several therapeutic approaches that target different components of the inflammatory response in CSU, including immunoglobulin E (IgE), type 2 cytokine signaling, and intracellular pathways involved in mast-cell activation.

Omalizumab, an anti-IgE monoclonal antibody, was discussed as an established treatment for patients who do not achieve adequate disease control with antihistamines.

Dupilumab, which inhibits signaling through the interleukin (IL)-4 receptor alpha subunit, was highlighted as another option, particularly when patients have coexisting atopic conditions.

The presenters noted that patients with overlapping inflammatory diseases, including atopic dermatitis (AD), may benefit from considering therapies that address multiple manifestations of type 2 inflammation.

Attention also turned to Bruton tyrosine kinase (BTK) inhibition, including remibrutinib, as an approach to reducing mast-cell activation.

BTK participates in intracellular signaling downstream of receptors involved in mast-cell activation. By inhibiting this pathway, remibrutinib may reduce the release of inflammatory mediators responsible for urticaria symptoms.

The discussion also addressed safety considerations associated with BTK inhibition, particularly bruising and bleeding.

Faculty explained that BTK contributes to platelet signaling, making it important to counsel patients about potential bleeding-related adverse events while distinguishing these effects from those associated with conventional anticoagulants.

Looking Beyond Histamine to Neuroimmune Signaling

Another major focus was the potential contribution of neuroimmune signaling to CSU symptoms.

The presenters described how mast-cell mediators can stimulate sensory nerve fibers, contributing to itching and other symptoms that may not be fully explained by histamine alone.

IL-31 was highlighted as a cytokine of interest because of its involvement in itch signaling and interactions with sensory neurons.

Faculty discussed the rationale for investigating therapies that interrupt these pathways, including JAK inhibitors and IL-31–targeted agents.

Although these approaches remain investigational for CSU, the discussion illustrated how a growing understanding of neuroimmune signaling may inform future therapeutic development.

Additional emerging approaches included barzolvolimab, an investigational monoclonal antibody targeting KIT, a receptor involved in mast-cell development and survival.

The presenters also reminded attendees that CSU can undergo spontaneous remission, making sustained symptom control and periodic reassessment important components of management.

One presenter summarized this approach by encouraging clinicians to "keep the hose on the fire until the fire goes out."

The analogy emphasized the importance of maintaining effective treatment while recognizing that the underlying disease may eventually remit.

Topical JAK Inhibitors Offer Steroid-Sparing Alternatives

The session then transitioned to nonsteroidal topical therapies, beginning with JAK inhibitors.

Faculty reviewed how topical JAK inhibition interrupts intracellular cytokine signaling involved in inflammation, itching, and skin-barrier dysfunction.

Ruxolitinib cream was highlighted for its role in AD and nonsegmental vitiligo, with the presenters emphasizing differences in the inflammatory pathways involved in each condition.

In AD, JAK inhibition can reduce signaling associated with type 2 cytokines and itch. In vitiligo, treatment targets pathways involving interferon gamma and downstream chemokines implicated in melanocyte destruction.

The discussion emphasized the importance of setting realistic expectations, particularly in vitiligo, where repigmentation may require sustained treatment.

"Vitiligo is a disease where you have to clear the soil before everything can grow back," one presenter explained.

The analogy highlighted the need to control the inflammatory environment before meaningful repigmentation can occur.

Faculty also reviewed delgocitinib cream, a topical pan-JAK inhibitor indicated for adults with moderate to severe chronic hand eczema when topical corticosteroids are inadequate or inappropriate.

The presenters highlighted its potential role in patients experiencing persistent itching, inflammation, and functional impairment despite previous topical treatment.

Across both medications, faculty emphasized the importance of understanding product-specific indications, application limits, and safety considerations when incorporating topical JAK inhibitors into practice.

PDE4 Inhibitors Expand Nonsteroidal Treatment Choices

Casquejo continued the discussion with an overview of topical PDE4 inhibitors, which modulate inflammatory signaling by preventing the breakdown of cyclic adenosine monophosphate (cAMP).

By inhibiting PDE4, these therapies increase intracellular cAMP levels, helping reduce the production of proinflammatory mediators while promoting anti-inflammatory signaling.

The presentation reviewed differences among topical PDE4 inhibitors, including crisaborole, roflumilast, and difamilast, with attention to formulation, dosing, efficacy, and tolerability.

Faculty highlighted the growing availability of creams, ointments, and foams, which may allow clinicians to tailor treatment to anatomical location, disease presentation, and patient preferences.

The discussion also addressed clinical trial findings demonstrating improvements in inflammatory disease severity and itching.

However, the presenters cautioned that differences in trial populations, study designs, and outcome measures should be considered when interpreting results across separate studies.

Application-site discomfort was discussed as an important tolerability consideration, particularly with certain formulations.

Casquejo also highlighted the potential value of topical PDE4 inhibitors as steroid-sparing options, including in pediatric patients and individuals requiring long-term management of chronic inflammatory skin disease.

The discussion reinforced the importance of considering both therapeutic efficacy and practical factors, such as formulation preference and treatment adherence, when selecting topical medications.

AhR Agonism: Supporting Skin-Barrier Function

The final therapeutic class discussed was AhR agonism, with a focus on tapinarof cream.

Unlike treatments that primarily inhibit inflammatory signaling, tapinarof was described as having multiple effects, including modulation of inflammatory cytokines, increased expression of skin-barrier proteins, and enhanced antioxidant activity.

Faculty explained that AhR activation can influence pathways involved in both plaque psoriasis and AD.

"It's not just downregulating cytokines; it's upregulating the skin barrier proteins such as filaggrin, and also upregulating antioxidant activity," a presenter explained.

The discussion also connected tapinarof's mechanism to the historical use of coal tar in psoriasis treatment, noting that both interact with the AhR pathway.

Faculty reviewed clinical evidence supporting tapinarof in plaque psoriasis and AD, including findings suggesting that some patients may maintain disease control for a period after discontinuing treatment.

This durability was highlighted as a potential advantage for patients who prefer simplified regimens or experience difficulty adhering to frequent topical applications.

The presenters also emphasized the potential utility of tapinarof in sensitive anatomical areas and as an adjunctive treatment for residual lesions in patients receiving systemic therapies.

Counseling Patients on Topical Treatment Expectations

The session concluded with practical considerations for incorporating nonsteroidal topical therapies into routine dermatologic care.

Although these medications provide alternatives to corticosteroids, faculty emphasized that patients still require counseling regarding appropriate application, anticipated response times, and potential adverse events.

For tapinarof, folliculitis was identified as a notable adverse event.

The presenter recommended applying a thin layer, rubbing the medication into affected areas, and following the direction of hair growth to help reduce follicular reactions.

Patients should also understand that visible improvement may take several weeks and that the full treatment response may develop gradually.

The discussion highlighted opportunities to incorporate nonsteroidal therapies into corticosteroid-sparing strategies, particularly for chronic disease management, sensitive anatomical sites, and patients who require additional control of residual inflammatory lesions.

Faculty also emphasized that treatment selection should consider the patient's ability to follow the prescribed regimen, as well as preferences regarding application frequency and formulation.

Translating Emerging Science Into Individualized Care

Across both CSU and inflammatory skin disease management, the session reinforced the importance of matching therapeutic mechanisms to individual patient characteristics.

For CSU, a growing understanding of mast-cell activation, type 2 inflammation, and neuroimmune signaling is informing the development of targeted therapies beyond conventional antihistamines.

Meanwhile, advances in topical JAK inhibition, PDE4 inhibition, and AhR agonism are expanding nonsteroidal treatment options for patients with AD, vitiligo, chronic hand eczema, and plaque psoriasis.

Butler, Casquejo, and Seiter emphasized the importance of considering disease phenotype, previous treatment response, safety, formulation preferences, and long-term management goals when selecting therapies.

Ultimately, the session demonstrated how continued advances in immunology and drug development are providing clinicians with additional tools to personalize treatment while addressing the practical challenges of managing chronic inflammatory skin diseases.

References

  1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766.
    https://doi.org/10.1111/all.15090
  2. Metz M, Giménez-Arnau A, Hide M, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984-994.
    https://doi.org/10.1056/NEJMoa2408792
  3. Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387(16):1445-1455. doi:10.1056/NEJMoa2118828.
    https://doi.org/10.1056/NEJMoa2118828
  4. Lebwohl MG, Kircik LH, Moore AY, et al. Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: The DERMIS-1 and DERMIS-2 randomized clinical trials. JAMA. 2022;328(11):1073-1084.
    https://doi.org/10.1001/jama.2022.15632
  5. Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024;91(3):457-465.
    https://doi.org/10.1016/j.jaad.2024.05.023
  6. Bissonnette R, Warren RB, Pinter A, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): Results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024;404(10451):461-473.
    https://doi.org/10.1016/S0140-6736(24)01027-4
  7. Casale TB, Saini SS, Ben-Shoshan M, et al. Dupilumab in patients with chronic spontaneous urticaria: Phase 3 LIBERTY-CSU CUPID randomized clinical trials. JAMA Dermatol. 2026;162(4):350-358.
    https://doi.org/10.1001/jamadermatol.2025.6023

Related to this article

Journal Digest: November 16
Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.